【レポートの概要（一部）】
1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease
3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2014-2024
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2013
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints
4. The Alzheimer’s Disease Drugs Market, 2014-2024
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2013
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2014-2024
4.4 The Alzheimer’s Disease Drugs Market Forecast 2014-2024
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2014-2024
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2014-2024
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2014-2024
4.8 Alzheimer’s Disease Drugs Pipeline, 2014
4.8.1 Recent High-Profile Failures of Clinical Trials for Alzheimer’s Disease Drug Candidates
4.8.1.1 Solanezumab (Eli Lilly)
4.8.1.2 LY-2886721 (Eli Lilly)
4.8.1.3 GSK2647544 (GSK)
4.8.1.4 Bapineuzumab (Elan/J&J/Pfizer)
4.8.1.5 Gammagard (Baxter)
4.9 FDA to Relax Rules for the Approval of Alzheimer’s Drugs
4.10 Will Novel Drug Development Strategies Prove Successful?
4.11 Promising Therapies in the Alzheimer’s Disease Drugs Pipeline, 2013
4.11.1 Solanezumab (Eli Lilly)
4.11.1.1Solanezumab Sales Forecast 2014-2024
4.11.2 Gantenerumab (Roche)
4.11.2.1The Gantenerumab Pipeline Forecast, 2014-2024
4.11.3 MK-8931 (Merck)
4.11.3.1 The MK-8931 Pipeline Forecast, 2014-2024
4.11.4 TTP488 (TransTechPharma)
4.11.5 LMTX (TauRx)
4.11.6 EVP-6124 (Forum Pharmaceuticals)
4.12 Deep Brain Stimulation (Functional Neuromodulation)
4.13 Leading Companies in the Alzheimer’s Disease Drugs Market, 2013
4.13.1 Pfizer, Inc
4.13.1.1Sales and Recent Performance Analysis, 2013
4.13.1.2 Pfizer: Aricept
4.13.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2 Eisai
4.13.2.1 Sales and Recent Performance Analysis, 2013
4.13.2.2 Eisai: Aricept
4.13.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
4.13.2.4 Collaboration with Biogen
4.13.2.5 Partnership with GE Healthcare for Diagnostic Development
4.13.3 Forest Laboratories (Acquired by Actavis)
4.13.3.1Acquisition by Actavis
4.13.3.2 Forest: Namenda
4.13.3.3 Namenda’s Sales and Recent Performance Analysis, 2013
4.13.4 Lundbeck A/S
4.13.4.1 Sales and Recent Performance Analysis, 2013
4.13.4.2 Lundbeck: R&D Capabilities
4.13.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
4.13.4.4 Lundbeck: Ebixa
4.13.5 Daiichi Sankyo
4.13.5.1 Financial Sales and Recent Performance, 2013
4.13.5.2 Daiichi Sankyo: Memary
4.13.6 Novartis AG
4.13.6.1 Sales and Recent Performance Analysis, 2013
4.13.6.2 Novartis: Exelon
4.13.6.3 eHealth Programme Delivering Innovation
4.13.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
4.13.7 TauRx
4.13.7.1 Partnership with Bayer Schering Pharma AG
4.13.8Transtech Pharma
4.13.8.1TTP Translational Technology
4.13.8.2 TranstechPharma: Alzheimer’s Disease Pipeline Portfolio
5. The Alzheimer’s Disease Diagnostics Market, 2014-2024
5.1 There is Still a Strong Market Need for Effective Diagnosis
5.2 The Alzheimer’s Disease Diagnostics Market, 2013
5.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2014-2024
5.4 The Alzheimer’s Diagnostics Market, 2014-2024
5.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
5.6 Biomarkers for Alzheimer’s Disease
5.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
5.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
5.7.1 Structural Imaging
5.7.2 Functional Imaging
5.7.3 Molecular Imaging Technologies
5.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
5.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
5.7.3.3 Flutemetamol (GE Healthcare)
5.7.3.4 Florbetaben (Piramal Imaging)
5.8 Other Alzheimer’s Diagnostics in Development
5.8.1 CSF Proteins
5.8.2 Blood Based Biomarkers for Alzheimer’s Disease
5.8.3 Genetic Risk Profiling
5.8.4 Eye Tests
5.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2014
5.9.1 Eli Lilly
5.9.1.1 Recent Performance and Sales Analysis, 2013
5.9.1.2 Alzheimer’s Disease Research Effort
5.9.1.3 Solanezumab
5.9.1.4 Amyvid (Florbetapir F18)
5.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
5.9.1.6 LY-2886721: Terminated Drug
5.9.1.7 N3pG-AB mAb:Phase I
5.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
5.9.2 Amarantus BioScience Holdings, Inc.
5.9.2.1 Recent Performance and Sales Analysis, 2013
5.9.2.2 LymPro
5.9.2.3 Intellectual Property Acquisitions
5.9.3 Piramal Enterprises
5.9.3.1Piramal Imaging SA
5.9.3.2 U.S. and EMA Approval of Florbetaben
5.9.3.3 Manufacturing and Distribution Agreements
5.9.4 GE Healthcare
5.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
5.9.4.2 Regulatory Approval of Flutemetamol
5.9.4.3 Licensing Agreements for Flutemetamol
5.9.5 Navidea
5.9.5.1 NAV4694 (Fluorine-18)
5.9.5.2 Collaboration Agreements
5.9.5.3 NAV4694 Clinical Development
5.9.6 Diagenic
5.9.6.1 Organisational Restructuring
6. The Leading National Markets, 2014-2024
6.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2013
6.1.1 The US and Europe Represent More than 70% of the Total Market
6.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2014-2024
6.3 Changing Market Shares of Leading National Markets 2014-2024
6.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.4.1 One in Eight Over the Age of 65 has AD in the US
6.4.2 The US Will Remain the Largest Market Over the Forecast Period
6.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
6.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-
2024
6.5.4 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, #
2014-2024
6.5.5 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast,
2014-2024
6.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast, 2014-2024
6.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
6.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2014-2024
7. Qualitative Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2014-2024
7.1 SWOT Analysis
7.2 Strengths
7.2.1 Alzheimer’s Disease is a High Profile Disease
7.2.2 Expanding Patient Population
7.2.3 Strong R&D Pipeline in Both Sectors of the Market
7.3 Weaknesses
7.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
7.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
7.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
7.4. Opportunities
7.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
7.4.2 Neurodegenerative Diseases Have Strong R&D
7.4.3 Emerging Markets Will Help Drive the Market
7.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
7.5 Threats
7.5.1 Patent Expiries Will Lead to Further Generic Competition
7.5.2 New AD Therapies Face Political, Commercial and Social Pressures
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threats of New Entrants
7.6.3 Powers of Suppliers
7.6.4 Bargaining Power of Buyers
7.6.5 Threat of Substitutes
8. Expert Opinions
8.1 Dr Simon Ridley, Head of Research, Alzheimer’s Research UK
8.1.1 Alzheimer’s Treatment in Late Stage Development
8.1.2 The Benefits of Alzheimer’s Diagnosis: A Future Prospect
8.1.3 Alzheimer’s and its Relationship with Other Diseases
8.1.4 Strategies to Incentivise Alzheimer’s Research and Investment
8.2 David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
8.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer’s
8.2.2 Alzheimer’s Disease Blood-based Biomarkers
8.2.3 Research Based Setting of the Simoa Technology
8.2.4 Quanterix: Alzheimer’s Partners and Collaborations
8.3 Elizabeth Edgerly, Ph.D., Chief Program Officer, The Alzheimer’s Association Northern California and Northern Nevada
8.3.1 Alzheimer’s Severe Under diagnosis
8.3.2 Novel Biomarkers: Critical for Alzheimer’s Diagnosis
8.3.3 Alzheimer’s Treatment Paradigm: Needs to be More Universally Effective
8.3.4 A Push to Improve the Success of Alzheimer’s Research
8.3.5 Alzheimer’s Treatment: The Greatest Challenge
9. Conclusions
9.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
9.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
9.3 Demographics Will Help Drive the Market Over the Forecast Period
9.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2014 to 2024
【レポート販売概要】
■ タイトル：世界のアルツハイマー病治療薬・診断市場予測■ 英文：ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies
■ 発行日：2014年8月
■ 調査会社：visiongain
■ 商品コード：VISG409044
■ 調査対象地域：グローバル
- スターター培養の世界市場予測：微生物別、用途別、組成別、フォーム別“The starter culture market is projected to grow at a CAGR of 5.3%; the key drivers include growth in the end-user industries such as dairy and dairy products, meat and sea food. Another key driver is the growing demand for dairy processing industries.”The global starter culture market size is estimated at USD 964 million in 2019 and projected to grow at a CAGR of 5.3% to reach USD 1,314 million b …
- 世界の航空宇宙分野向けロボット市場動向（2012-2016）TechNavio's analysts forecast the Global Aerospace Service Robotics market to grow at a CAGR of 24.11 percent over the period 2012-2016. One of the key factors contributing to this market growth is the development of telerobotics for space. The Global Aerospace Service Robotics market has also been witnessing an increase in the demand for unmanned aerial vehicles. However, rapid technological chan …
- 世界のプロピレン生産能力および投資動向Global Propylene Capacity and Capital Expenditure Outlook - China and US to drive Propylene Industry Expansion Summary Global propylene capacity will experience considerable growth in the next five years with increase from 101.3 MMTPA in 2014 to 127.1 MMTPA by 2019. Large capacity additions with more than 50 planned projects are expected to come online primarily in the China, US and Iran in the ne …
- Chronic Obstructive Pulmonary Disease (COPD)：グローバル臨床試験レビューH2, 2013Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2013" provides data on the Chronic Obstructive Pulmonary Disease (COPD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chroni …
- 組織検査の世界市場2016-2020About Tissue Diagnostics Tissue diagnostics involves the diagnosis of diseases or analysis of the biological causes of the disease by extracting and analyzing a specific tissue. It has a broad range of applications in clinical research, clinical diagnostics, and cell biology. It is considered one of the most accurate techniques for the diagnosis of inflammatory conditions. Medical specialists part …
- マイクロディスプレイの世界市場：OLED、LCoS、LCD、DLPThe microdisplays technology enhances the quality of images and videos in spite of the small dimension of the screen. The global microdisplays market is expected to reach USD 1.5 billion by 2020, at a CAGR of 23.3% between 2015 and 2020. In terms of geography, North America is estimated to hold a large market share of ~57% in 2015 mainly because of the development in the U.S., followed by APAC and …
- バナナパウダーの世界市場展望2017-2026According to Stratistics MRC, the Global Banana Powder Market is accounted for $524.47 million in 2017 and is expected to reach $759.50 million by 2026 growing at a CAGR of 4.2% during the forecast period. Some of the key factors influencing the market are growing number of diet conscious in consumers, increase in the production of the green banana and numerous health benefits associated with bana …
- クリプトコッカス症(Cryptococcosis)：治療薬開発パイプライン動向（2015年上半期版）Cryptococcosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Cryptococcosis - Pipeline Review, H1 2015’, provides an overview of the Cryptococcosis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cryptococcosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action ( …
- オフショアデコミッショニングの世界市場2018-2022About Offshore Decommissioning Offshore decommissioning consists of a series of steps to close an oil and gas facility. Major processes in offshore decommissioning include dismantling, waste transportation, and site treatment and reuse. An offshore oil and gas facility takes several decades to be completely decommissioned depending on the process chosen, with these processes spread out over the ye …
- 航空機塗装の世界市場予測（～2022）The aerospace coatings market is projected to reach USD 1.98 Billion by 2022, at a CAGR 6.90% from 2017 to 2022. A coating is a covering that is applied to the surface of an object, usually referred to as a substrate. The purpose of applying the coating may be decorative, functional, or both. The aerospace coatings market is largely driven by increased demand for aerospace coatings from various en …
- セイボリースナック菓子の世界市場2015-2019About savory snacks Savory snacks are snacks that are salty. Ingredients used in savory snacks include potatoes, corn, nuts, seeds, wheat, rice, tapioca, and oats. Though there are many variants in terms of ingredients used, the savory snacks market can be divided into eight major categories: potato chips, extruded snacks, nuts and seeds, traditional snacks, popcorn, pretzels, meat snacks, and oth …
- 2014年市場分析：日本の肝炎診断Complete report $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500.The report presents a detailed analysis of the Hepatitis diagnostics market in Japan. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, An …
- 一次リチウム電池の世界市場2018-2022About this market The rising demand for medical equipment, which includes surgeries and operations demand for batteries that have a long battery life and can be disposed after use. The growing popularity of primary lithium batteries among medical devices manufactures due properties such as small size battery, easy to operate and lightweight. The heart monitoring system requires battery backup solu …
- 世界の航空用締結具（ファスナー）市場（2014-2018）TechNavio's analysts forecast the Global Aerospace Fasteners market to grow at a CAGR of 7.75 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing demand for commercial aircraft in the APAC region. The Global Aerospace Fasteners market has also been witnessing the rise in demand for LCCs. However, the increase in raw material prices could p …
- 世界のゲルマニウム及びゲルマニウム製品市場2015The Global Germanium and Germanium Products Industry Report 2015 is a professional and in-depth study on the current state of the Germanium and Germanium Products industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Germanium and Germanium Products market analysis is provided for the international marke …
